Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.82T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥3.56T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥27.2bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥35.1bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥64.6bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥39.8bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥21.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥41.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥27.6bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.88Tat 2024-09-30Cons.Assets
Total assets¥1.80Tat 2024-03-31Cons.Assets
Total assets¥1.82Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.12Tat 2024-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2024-03-31Cons.Liabilities
Net assets / equity¥757.7bnat 2024-09-30Cons.Net assets
Net assets / equity¥736.6bnat 2024-03-31Cons.Net assets
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥251.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥230.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥249.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥228.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥41.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥25.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥103.942024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.832023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio32.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥161m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥600.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥600.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥201m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥11.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.83T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.82T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥27.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)塚原 克哲
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)御厨 健太郎
Cpa3 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)今井 仁子
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration1778989000000JPY
Net sales (5-year summary)CurrentYTDDuration1824672000000JPY
Net sales (5-year summary)Prior1YearDuration3558732000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration29299000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration35080000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration64570000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration17154000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration21727000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration41474000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration30883000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration35271000000JPY
Comprehensive income (5-year summary)Prior1YearDuration64684000000JPY
Net assets (5-year summary)Prior1QuarterInstant714616000000JPY
Net assets (5-year summary)CurrentQuarterInstant757655000000JPY
Net assets (5-year summary)Prior1YearInstant736612000000JPY
Total assets (5-year summary)Prior1QuarterInstant1815781000000JPY
Total assets (5-year summary)CurrentQuarterInstant1879759000000JPY
Total assets (5-year summary)Prior1YearInstant1799127000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration80.48
Basic earnings loss per share (5-year summary)CurrentYTDDuration103.94
Basic earnings loss per share (5-year summary)Prior1YearDuration195.83
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.321
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.329
Equity to asset ratio (5-year summary)Prior1YearInstant0.334
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration31215000000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration41832000000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration61843000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-10800000000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration-6520000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-7817000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration-12738000000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration-14376000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration-25248000000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant206983000000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant249016000000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant228084000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember219226042
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember219226042
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant219226042
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant219226042
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember28728000

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass